Sangamo Therapeutics Inc
(LTS:0R1D)
$
2.18
-0.06 (-2.68%)
Market Cap: 492.41 Mil
Enterprise Value: 480.93 Mil
PE Ratio: 0
PB Ratio: 12.55
GF Score: 41/100 Sangamo Therapeutics Inc at Jefferies Gene Therapy/Editing Summit Transcript
Oct 08, 2019 / 03:15PM GMT
Release Date Price:
$9.53
Maury Raycroft
Jefferies LLC - Analyst
Okay, my name is Maury Raycroft and I am one of the biotech analysts at Jefferies. And I'd like to welcome Sandy Macrae, the CEO of Sangamo Therapeutics. Thanks for joining us today, Sandy.
Sandy Macrae
Sangamo Therapeutics, Inc. - President & CEO
It is a pleasure to be here.
Questions & Answers
Maury Raycroft
Jefferies LLC - Analyst
Great. And so we are going to do a fireside chat. Maybe to start it off, if you can give an overview of Sangamo's pipeline for people that are new to the story, and what are important catalysts for the next 6 to 12 months.
Sandy Macrae
Sangamo Therapeutics, Inc. - President & CEO
So Sangamo is a fascinating Company. We are the genomic medicine company. We are known for our zinc fingers and our editing capabilities and editing is core of what we do. But if you can do editing, you can do a range of different things through our knowledge of genomic manipulation and AAVs and taking
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot